The sentences the FDA quoted in its August 24, 2026 letters to Royal Peptides LLC, NuScience Peptides LLC and Peptide Partners LLC tend to share a shape.
A verb and an effect in the body
Most quoted lines pair a verb that claims a result (“has led to,” “may result in,” “helps,” “can kill”) with something happening in the body: weight, blood sugar, organs, sexual function. The word “may” did not keep a line out: Royal Peptides wrote that retatrutide “may result in up to 24.2% body weight reduction.” From the Peptide Partners letter, tirzepatide “has direct protective effects on the kidneys, which could be beneficial for patients with diabetic kidney disease.”
A number and a time frame
The sharpest examples add a measured result over time. From the Royal Peptides letter: “In studies, Tirzepatide has led to up to 22.5% body weight reduction in participants over 72 weeks…” The other two letters do not quote figures like these.
Research language did not change it
Many quoted lines open with research framing. The FDA quoted this NuScience line anyway: “Preclinical studies in rodent models have demonstrated its efficacy in promoting weight loss and improving glycemic control.”
Not every quoted line fit the pattern. The FDA also listed a Royal Peptides category description of semaglutide that claims no result. This is a pattern drawn from three letters, not a legal test, and a sentence that fits none of it is not safe because of it. The FDA says its letters are not an all-inclusive list of violations.
Alexios reviews a shop’s website for the kinds of wording and product pairings described in these letters, before the shop applies to take card payments. A review does not guarantee any outcome with the FDA or with a payment company.
This article describes public FDA letters. It is not legal advice.
Sources
- FDA warning letter, Royal Peptides LLC, reference 734884, dated August 24, 2026, posted September 1, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026
- FDA warning letter, NuScience Peptides LLC, reference 733652, dated August 24, 2026, posted September 1, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026
- FDA warning letter, Peptide Partners LLC, reference 735063, dated August 24, 2026, posted September 1, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026